

Beyond Glycan Control: The IVGE Advantage in Key Biopharma Applications

Source: Roche CustomBiotech

In the dynamic and highly scrutinized world of biopharmaceutical manufacturing, an ongoing challenge continues to take center stage: glycosylation. Effectively controlling glycans during bioprocessing is considered a critical quality attribute by regulatory bodies due to their profound impact on safety, efficacy, and stability. In some cases, improper glycosylation can even trigger unwanted immune responses, or immunogenicity, in patients.¹ For these reasons and more, the inherent variability and complexity of glycosylation analysis and control is a constant and high-stakes endeavor during bioprocessing. Traditional methods for controlling glycosylation are inefficient and imprecise, leading to inconsistent products and batch variability.^{2,3}

A powerful and versatile alternative to legacy approaches is In Vitro Glycoengineering (IVGE). This technology offers a reliable and robust solution for optimizing biopharmaceutical workflows throughout the entire development and biomanufacturing life cycle. **By providing precise control over glycosylation**, IVGE stands ready to advance the next generation of protein-based drugs.³ This paper will explore key therapeutic areas where IVGE is not merely an improvement, but a critical enabling technology.

Exploring the Expansive Reach of IVGE

Given the intricate nature of glycosylation, a one-size-fits-all approach to biomanufacturing is not a viable strategy for achieving predictable and reproducible outcomes. While traditional methods offer some control, they often fall short in delivering the precision needed to guarantee a consistent and high-performing product. This lack of control has historically limited the potential of many protein-based therapies. IVGE, however, provides an unprecedented level of control, empowering scientists to move beyond simply managing glycosylation to actively engineering it for specific therapeutic objectives.

IVGE's transformative capability and its versatility allow it to address a broad spectrum of challenges, from optimizing bioprocessing and creating "better" biologics to unlocking new possibilities in cell and gene therapy and vaccine development. Its ability to solve specific, long-standing industry challenges

makes IVGE a pivotal platform that can enhance diagnostic capabilities and possibilities.

One critical area of opportunity is in the development of biosimilars, which could expand patient access to high-cost biologics but includes immense analytical and regulatory challenges. These follow-on biologics must demonstrate analytical similarity to the originator drug, including having an identical or near-identical glycan profile. Traditional bioprocessing approaches struggle to replicate this profile consistently across batches and often result in significant variability that requires extensive (and expensive) non-clinical and clinical testing. IVGE directly tackles this by enabling the precise adjustment of the final product's glycan structure as a downstream process, demonstrating high similarity to the reference product and thus helping reduce the regulatory burden and speeding up market entry.

The table below breaks down some of the applications within bioprocessing where IVGE offers a powerful solution with clear advantages.

IVGE Function	Field of Application	Pain Point	Limitation(s) of Current Methods	How IVGE Helps
Glycan Homogeneity	Antibody engineering ⁴ , Vaccine development ^{5,6}	Inconsistent glycosylation patterns can lead to batch variability and can weaken an immune response	Produces heterogeneous glycoproteins, making it difficult to control the exact antigen structure	Ensures glycan homogeneity by creating a single, well-defined molecular structure using specific enzymes to add or remove sugar molecules after the protein is produced.
Half-Life Extension	Antibody engineering ⁸ , Biobetter engineering ^{7,8}	Many therapeutic proteins have a short half-life, requiring frequent, high-dose administration	Current methods like PEGylation are effective but have significant drawbacks (e.g., reduced efficacy, heterogeneity)	Extends half-life extension by creating specific, stable glycoforms, while avoiding the pitfalls associated with PEGylation.
Analytical Similarity	Biosimilar engineering ⁷	Manufacturing variability makes it difficult to replicate the complex glycan profile of the originator biologic with a high degree of precision	The “process is the product” for biologics, meaning small changes in manufacturing can lead to differences in the final product’s glycan structure	Facilitates glycan adjustment as a downstream process to ensure the final product’s glycosylation profile matches the originator, significantly reducing the regulatory burden of trials, testing, and paperwork.
Cell Homing & Persistence	Cell & gene therapy ^{4,6}	Cell therapies face challenges with persistence and targeting due to immune system clearance	Lack the capability and control needed to accurately and selectively engineer the complex surface of a living cell	Enhances cell homing and persistence through the highly specific enzymatic modification of cell surface glycans to optimize persistence and targeting
Immunogenicity	Vaccine development ⁵	The variable glycan structures on vaccine antigens can lead to a weak or unfocused immune response	Produces heterogeneous glycoproteins, making it difficult to control the exact antigen structure	Improves immunogenicity by ensuring a single, specific glycoform, which elicits a stronger, more targeted, and more effective antibody response
Lysosomal Targeting	Enzyme replacement therapy ⁹	Therapeutic enzymes often lack the specific glycan signals (e.g., mannose-6-phosphate precursors) needed for cellular uptake and delivery to the lysosome	May bolster stability but can compromise the enzyme’s activity	Enables therapeutic function by precisely engineering the glycan structure to boost the enzyme’s stability and half-life and create the essential targeting moieties for cellular uptake and delivery
Brain penetration	CNS therapeutics ¹⁰	Drug delivery to the brain is blocked by the blood-brain barrier’s (BBB) efflux mechanisms	Focus on enhancing influx (entry) and often fail due to drug efflux or toxicity issues	Increases therapeutic drug concentration in the brain by modifying glycan structures to inhibit drug efflux across the BBB

Roche CustomBiotech, a leader in the biopharma industry, has developed an **IVGE toolbox** that is designed for specific and efficient alteration of sugar moieties. This portfolio of highly pure and active glycosyltransferases and well-characterized activated sugars enables precise modifications and fine-tuning of glycan structures to meet the stringent quality and manufacturing requirements of the biopharmaceutical industry.¹¹ By uncoupling glycosylation from the upstream bioprocess, IVGE technology allows manufacturers to optimize product yield and consistency while also enriching for desired glycoforms downstream.

A New Era of Precision With IVGE

As the field of biologics continues to grow, the need for precise control over post-translational modifications is paramount. Although traditional methods still have their place, IVGE represents a significant leap forward by **enabling the precise engineering of protein properties**, ultimately elevating the standard for developing more effective and safer therapeutics.



Ready to take control of your glycosylation? Explore the IVGE toolbox from Roche CustomBiotech [here](#).

References

1. Zhou Q, Qiu H. The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. J Pharm Sci. 2019;108(4):1366-1377. <https://doi.org/10.1016/j.xphs.2018.11.029>
2. Wilkinson H, Saldo R. Current Methods for the Characterization of O-Glycans. J Proteome Res. 2020;19(10):3890-3905. <https://doi.org/10.1021/acs.jproteome.0c00435>
3. Thomann M, et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One. 2015;10(8):e0134949. <https://pubmed.ncbi.nlm.nih.gov/26266936/>
4. Ivanova, A. and Falcioni, F. (2022). Challenges and opportunities for the large-scale chemoenzymatic glycoengineering of therapeutic n-glycosylated monoclonal antibodies. Frontiers in Catalysis, 1. <https://doi.org/10.3389/fctls.2021.810779>
5. Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology. 2020 Dec 9;30(12):981-988. doi: 10.1093/glycob/cwaa042. PMID: 32363391; PMCID: PMC7239183. <https://pubmed.ncbi.nlm.nih.gov/32363391/>
6. Wu J, Wang X, Huang Y, Zhang Y, Su S, Shou H, Wang H, Zhang J, Wang B. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proc Natl Acad Sci U S A. 2023 Sep 19;120(38):e2300366120. doi: 10.1073/pnas.2300366120. Epub 2023 Sep 11. PMID: 37695897; PMCID: PMC10515149. <https://pubmed.ncbi.nlm.nih.gov/37695897/>
7. Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1. PMID: 21285536; PMCID: PMC3092613. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3092613/>
8. Kumari, M., Sahni, G., & Datta, S. (2020). Development of site-specific pegylated granulocyte colony stimulating factor with prolonged biological activity. Frontiers in Bioengineering and Biotechnology, 8. <https://doi.org/10.3389/fbioe.2020.572077>
9. Goettig P. Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Int J Mol Sci. 2016 Nov 25;17(12):1969. doi: 10.3390/ijms17121969. PMID: 27898009; PMCID: PMC5187769. <https://pubmed.ncbi.nlm.nih.gov/27898009/>
10. Finke JM, Ayres KR, Brisbin RP, Hill HA, Wing EE, Banks WA. Antibody blood-brain barrier efflux is modulated by glycan modification. Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2228-2239. doi: 10.1016/j.bbagen.2017.06.008. Epub 2017 Jun 15. PMID: 28624473; PMCID: PMC5557653. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5557653/>
11. Sebastian, Malik & Thomann, Marco. (April 2016). In vitro glycoengineering – Suitability for Biopharma manufacturing. <https://custombiotech.roche.com/global/en/post-listing/in-vitro-glycoengineering---suitability-for-biopharma-manufactur.html>

Regulatory and license disclaimers, warranty limitations and legal notes
are listed on the respective product page on custombiotech.roche.com

© 2025
All rights reserved.

Published by
Roche Diagnostics GmbH
Sandhofer Str. 116
68305 Mannheim
Germany

custombiotech.roche.com

**Please contact your local
CustomBiotech representative**

Europe, Middle East, Africa, Latin America
mannheim.custombiotech@roche.com

United States
custombiotech.ussales@roche.com

Canada
custombiotech.can@roche.com

Asia Pacific
apac.custombiotech@roche.com